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Abstract
The high frequency of p53 mutation in human cancers indicates the important role of p53 in
suppressing tumorigenesis. It is well established that the p53 regulates multiple, distinct, cellular
functions such as cell cycle arrest and apoptosis. Despite intensive studies, little is known about
which function is essential, or if multiple pathways are required, for p53-dependent tumor
suppression in vivo. Using a mouse brain carcinoma model that shows high selective pressure for
p53 inactivation, we found that even partially abolishing p53-dependent apoptosis by Bax
inactivation was sufficient to significantly reduce the selective pressure for p53 loss. This finding
is consistent with previous reports that apoptosis is the primary p53 function selected against
during Eμ-myc induced mouse lymphoma progression. However, unlike observed in the Eμ-myc
induced lymphoma model, attenuation of apoptosis is not sufficient to phenocopy the aggressive
tumor progression associated with complete loss of p53 activity. We conclude apoptosis is the
primary tumor suppressive p53 function and the ablation of additional p53 pleiotropic effects
further exacerbates tumor progression.
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Introduction
p53 is frequently mutated in a wide array of human cancers (Hollstein et al., 1991; Petitjean
et al., 2007). A variety of cell stresses, such as DNA damage, hypoxia, or cell-cycle
aberrations, evoke a p53 transcriptional response, which modulates multiple physiological
pathways, including cell-cycle arrest, apoptosis, genome surveillance, senescence, and
angiogenesis (Dameron et al., 1994; Ko and Prives, 1996; Levine, 1997; Vogelstein et al.,
2000; Vousden and Lu, 2002). The pleiotropic effects of p53 make it difficult to distinguish
whether a single p53-dependent function is uniquely responsible for the active selection
against p53 activity during tumorigenesis, or if selective pressure is directed against the
p53’s aggregate activities, since loss of any one or combination of these functions could
account for the prevalence of p53 mutations among human cancers.
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Several investigators (Eischen et al., 2001; Hsu et al., 1995; Post et al., 2009; Schmitt et al.,
2002; Sluss et al., 2010) have attempted to dissect the functions of p53 in vivo using the Eμ-
myc transgenic mouse model of B-cell lymphoma (Harris et al., 1988) in which the
immunoglobulin heavy chain enhancer drives expression of c-myc. In these lymphomas,
apoptosis is the essential p53-dependent function suppressing tumor progression (Eischen et
al., 2001; Schmitt et al., 2002). Reduced activity of Bax, a downstream effector of p53-
mediated apoptosis, circumvented p53 mutations usually acquired during progression
(Eischen et al., 2001). Further evidence for the importance of apoptosis on the selective
pressure against p53 is the reduced frequency of p53 loss of heterozygosity (LOH) in
lymphomas that harbor a single p53 null allele (Eμ-myc;p53+/−) (Schmitt et al., 2002). Over-
expressing either the Bcl2 gene or a dominant-negative form of caspase 9 blocks apoptosis
and dramatically reduces p53 LOH. Moreover, lymphomas in which apoptosis is completely
abolished acquire an aggressive Eμ-myc phenotype, despite retention of the wild type p53
allele, indicating reduced apoptosis not only reduces selective pressure against p53, but is
also sufficient for lymphoma progression.
Whether apoptosis is the essential p53-dependent tumor suppressive function in epithelium-
derived carcinomas has not been studied in vivo. Here we investigated the selective pressure
against p53 activity using a brain cancer model we previously described (Chen and Van
Dyke, 1991). In this model, we directed expression of a truncated SV40 T antigen (T121) in
the mouse choroid plexus epithelium (CPE), and evaluated the effects of p53 loss on tumor
progression. The CPE lines the ventricles of the mammalian brain, forming the blood-brain
barrier, and produces cerebral spinal fluid. Normally, CPE cells cease dividing within two
weeks of birth. The T121 oncoprotein specifically inactivates pRb-related pocket proteins
(pRb, p107, and p130), which causes cell-cycle re-entry. The unscheduled proliferation
triggers apoptosis or predisposes cells to dysplastic growth followed by progression to
carcinoma (Chen and Van Dyke, 1991; Symonds et al., 1994).
p53 plays a significant role in suppressing tumorigenesis in transgenic (Tg)T121 mice.
Removing p53 activity greatly reduces the apoptosis elicited by T121 expression in this brain
tumor setting, with approximately half the apoptosis mediated by the p53 effector gene, Bax
(Symonds et al., 1994; Yin et al., 1997). TgT121 mice heterozygous or homozygous for a p53
null allele develop CPE tumors with shorter latency than TgT121 mice with wild type p53
alleles. There is immense selective pressure to inactivate the functional p53 alleles in both
TgT121;p53+/− (100%) and TgT121;p53+/+ (38%) CPE tumors (Lu et al., 2001; Symonds et
al., 1994). Furthermore, all tumors from TgT121;p53+/− and TgT121;p53+/+ mice that
inactivate p53 were highly angiogenic, yet tumors lacking p53 activity displayed little or no
aneuploidy (Lu et al., 2001), contrary to the widely held view that p53 is largely responsible
for surveying genomic integrity.
The correlation between accelerated tumor progression and decreased apoptosis suggests a
critical role for apoptosis in executing tumor suppression by p53 in our brain tumor model.
However, other p53-mediated functions, such as angiogenesis inhibition (Yin et al.,
unpublished results), or senescence may also subject the cell to selective pressure for p53
loss. In the present study, we explored the significance of p53-dependent apoptosis in CPE
tumor suppression. We hypothesized lower apoptosis levels should decrease selective
pressure for p53 loss. We show reducing Bax-mediated apoptosis does indeed prevent the
loss of p53 activity; whereas, deficiency of an alternative p53-effector not involved in
apoptosis, p21, does not alleviate selective pressure against p53. Loss of p53-dependent
apoptosis, however, is not sufficient for progression to the more aggressive brain tumor
phenotype associated with the complete absence of p53 activity. The subsequent loss of
pleiotropic p53 functions allows tumors to acquire additional, distinct tumor phenotypes.
While the influence of p53 effectors is likely cell type- and condition-specific, apoptosis
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serves as the primary p53 function that is actively selected against during tumor progression
in both our brain carcinoma model and the Eμ-myc lymphoma model.
Materials and Methods
Mice
TgT121 transgenic mice (C57BL6/J; DBA2, F1 hybrid background) were previously
described (Chen and Van Dyke, 1991; Saenz Robles et al., 1994; Symonds et al., 1994).
Bax−/− mice (C3H), p53−/− (C57BL6/J) and p21−/− (C57BL6/129 hybrid) mice have been
described (Brugarolas et al., 1995; Jacks et al., 1994; Knudson et al., 1995). TgT121;Bax−/−
and TgT121;Bax+/− mice were generated by mating male TgT121 mice with female Bax−/−
mice (Male Bax−/− mice are infertile). TgT121;Bax+/−;p53+/− , and TgT121;Bax−/−;p53+/−
mice were generated by mating TgT121;Bax+/− with p53+/− or p53−/− and interbreeding
their progeny. TgT121;Bax−/− females were not used in breeding because they die around 2–
3 months (Yin et al., 1997). TgT121;p53+/−;p21+/− mice and TgT121;p53+/−;p21−/− mice
were produced by mating TgT121;p53+/− mice with TgT121;p21−/− mice and interbreeding
their progeny.
Because the Bax null and TgT121 stock mice are maintained distinct background strains
(C3H and c57BL6/DBA2 hybrid, respectively), we included in our analysis TgT121;Bax+/+
sibling controls to avoid the potential pitfall of comparing tumors among mice of mixed
genetic background strains.
Histology
Mouse brains were fixed in 10% formalin, embedded in paraffin, and cut in 5 0 µm sections.
To examine tumor morphology, brains were sectioned for 6 to 10 consecutive layers with a
50 µm interval between each layer, and then 5 µm sections from each layer were stained
with hematoxylin and eosin.
RNA in situ hybridization
Sections were treated and hybridized as previously described (Lu et al., 2001). The p21 anti-
sense probe was generated by T7 transcription of an EcoRI-linearized pBS-KSp21 template.
The Bax anti-sense probe was generated by T3 transcription of a ApaI-linearized pBS-
SKpBax template. Probes were labeled with [γ-35S] UTP (5×104 cpm/µl) and hybridized to
slides at 50°C overnight. Slides were exposed for 3 days (p21) or 8 weeks (Bax).
p53 immunohistochemistry
Paraffin embedded sections were boiled in Trilogy buffer (Cell Marker, Arkansas) for 15
min and then cooled at room temperature for 30 min. Sections were blocked in 10% normal
goat serum (NGS) in phosphate buffered saline for 1 h at room temperature. Sections were
incubated with rabbit anti-mouse p53 polyclonal antibody (Novocastra Laboratories Ltd.,
UK) at 1:600 dilution in 10% NGS at 4°C overnight. The secondary antibody staining and
peroxidase enzymatic reaction were performed using an ELITE kit (Vector Laboratories
Inc., California). After applying the DAB substrate, sections were incubated for 3–6 min and
the staining was monitored by microscopy. Slides were counterstained with methyl green.
Statistical Analysis
Fisher’s exact test was used to evaluate the significance of differences in p53 inactivation
frequencies between tumors derived from alternative genotypes. p-values less than 0.05
were deemed significant.
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To assess whether apoptosis is the essential p53 tumor suppressor function selected against
during brain tumor progression, we examined the frequency of p53 inactivation in TgT121
mice with Bax deficiency. Bax mediates nearly half of apoptosis in this brain tumor model
(Yin et al., 1997), although, Bax deficiency alone, without TgT121, does not cause abnormal
proliferation or tumorigenesis in CPE. We assessed p53 activity two ways: first, we
evaluated the histology of TgT121 CPE tumors as an indicator of the tumor’s p53 status, as
we have previously determined that p53 activity directly correlates with tumor histology in
this model (Lu et al., 2001). Second, we assayed gene expression levels of the p53 target
gene, p21 (el-Deiry et al., 1993). A functional assessment of p53 status is important since
diverse mutations could render p53 inactive. Importantly, we have shown that p21
transcription depends on p53 activity, and p21 does not play a direct role in p53-dependent
apoptosis in this brain carcinoma model (Lu et al., 2001).
TgT121 mice develop tumors with two distinct morphologies we designated Type I and Type
II tumors (Table 1), which we previously demonstrated correspond to p53 functional status
(Lu et al., 2001): Type I tumors invariably show loss of p53 function (100%, n=34 tumors),
while Type II tumors retain p53 function. Type I tumors have greater tumor volume and
higher cell density, with abundant blood vessels and perivascular polarity, whereas Type II
tumors show a dysplastic morphology and pleomorphic nuclei, with overall smaller tumor
volume and fewer blood vessels. Type I tumors are more rare than Type II tumors in TgT121
mice (38% vs. 62%, respectively), presumably because the Type I phenotype requires loss
of both active p53 alleles.
To test the effect of reducing Bax-mediated apoptosis on brain tumor histology, we
generated TgT121 mice that differed with respect to their Bax genotype (+/+, +/−, −/−). We
confirmed that the histological characteristics of tumors derived from TgT121,Bax+/+ sibling
mice were consistent with our previous observations of TgT121 mice, for both the Type I
(Fig. 1 A, C) and Type II (Fig. 1 B, D) tumors, despite the mixed genetic backgrounds
generated by intercrossing the two mouse strains. Importantly, the mixed genetic
background in the present study had little effect on the tumor spectrum we previously
reported. The frequency of Type I tumors in TgT121;Bax+/+ mice is 35% (n=16), very
similar to our previous observation in TgT121 mice (38%) (Lu et al., 2001). Using the tumor
frequencies of TgT121;Bax+/+ mice as a baseline for comparison, we scored the tumor
morphologies among TgT121;Bax+/− and TgT121;Bax−/− mice. For both heterozygous and
homozygous mice, Bax gene status significantly altered the spectrum of TgT121 tumors
relative to Bax wild type mice (p < 0.05). Among TgT121;Bax+/+ control mice (n=17) 35%
of tumors were Type I. In contrast, among TgT121;Bax+/− mice (n=40) the percentage of
Type I tumor was reduced to 12.5%, and among TgT121;Bax−/− mice (n=14), we observed
no Type I tumors (Fig. 1 E). Consistent with our hypothesis, when apoptosis was reduced
through lower Bax levels, fewer tumors displayed the Type I phenotype that is associated
with complete loss of p53 function.
To confirm our histological assessment of p53 activity, we assayed p21 expression levels as
a second indicator of p53 function, since p21 expression depends on p53 in this system (Lu
et al., 2001; Pan et al., 1998). We measured p21 expression using RNA in situ hybridization
in tumors from TgT121;Bax+/+ (n= 8 Type I and n=8 Type II ), TgT121;Bax+/− (n= 4 Type I
and n=2 Type II ) and TgT121;Bax−/− (n= 4 Type I and n=2 Type II ) mice. Consistent with
the morphological assessments, all Type I tumors lost p21 expression, while the Type II
tumors maintained p21 expression (Fig. 2). The p21 sense probes did not show signal above
background (data not shown). These results are summarized in Fig. 5A. Taken together, our
analysis of tumor histology and p21 gene expression indicate that although Bax mediates
Lu et al. Page 4













only half of p53-dependent apoptosis in our brain tumor model, reduced Bax activity greatly
reduces the frequency of p53 inactivation.
Next, we assayed the frequency of p53 inactivation in tumors of mice that harbored a single
engineered mutant p53 allele. The rationale for these experiments was twofold: First, with
only a single p53 allele, tumors would be more susceptible to complete loss of p53 function,
thus making a more sensitive assessment of p53 activity levels. Indeed, 100% of tumors
derived from TgT121;p53+/− mice progress to the Type I phenotype and virtually all (94%)
lose the active p53 allele (Lu et al., 2001). Our second rationale was based on our
observation that the majority of TgT121;Bax−/− mice (12 out of 14) developed severe
hydrocephaly (Fig. 1F) which could also contribute to a shorter lifespan, in addition to CPE
tumorigenesis. The median survival time of Bax null mice (TgT121;Bax−/−) is considerably
shorter than TgT121;Bax+/+ mice (t50= 12 vs. 31 weeks, Fig. 3A,B). The shortened
timeframe among the TgT121;Bax−/− mice might be insufficient to allow tumor cells to lose
both p53 alleles and display the Type I tumor phenotype; although, we know that Type I
CPE tumors can develop in TgT121 mice as early as 8 to 9 weeks (Lu et al., 2001 and Lu
unpublished data).
We generated both TgT121;Bax+/−;p53+/− and TgT121;Bax−/−;p53+/− mice and, as above,
characterized p53 inactivation by evaluating tumor histology (Fig. 4 A, C) and p21
expression (Fig. 4 B, D). Bax heterozygosity (TgT121;Bax+/−;p53+/− ), only modestly
reduced the incidence of Type I tumors we previously observed among mice wild type for
Bax (i.e. TgT121;p53+/−) (87% vs. 100%, respectively) (Fig. 3 C). In stark contrast, and
consistent with our prediction, the incidence of Type I tumors (20%) was greatly reduced
among Bax nullizygous mice (TgT121;Bax−/−;p53+/−) (Fig. 3 C). Moreover, the lower
frequencies of Type I tumors observed in animals with reduced Bax activity
(TgT121;Bax+/−;p53+/− and TgT121;Bax−/−;p53+/−) indicates a bona fide shift in tumor
spectrum, and not an artifact caused by the co-morbidity of hydrocephaly, since
TgT121;p53+/− mice develop Type I tumors with a latency (t50 = 9 weeks) within the
expected lifespan of Bax null mice (Fig. 3 C,D and Lu et al., 2001). Furthermore, p21
expression directly correlates with differences in tumor morphology, as we have shown
previously (Lu et al., 2001), and therefore serves as an indicator of p53 functional status.
Taken together, these results are consistent with a model in which reduced Bax-mediated
apoptosis alleviates selective pressure against p53 even in the context of tumors sensitized to
p53 loss.
As an additional control for these experiments, we also assessed the effects of loss of p21, a
p53 downstream cell cycle arrest gene, on selective pressure against p53 activity. We
reasoned if selective pressure is working primarily against p53 apoptotic activity, then the
incidence of Type I tumors should remain high even when we mutate a p53-effector that is
not involved in apoptosis. p21 deficient mice are more prone to tumorigenesis in multiple
tissues at old age (Martin-Caballero et al., 2001). However, p21 does not contribute to p53-
induced apoptosis in the TgT121 brain tumor model in the absence of DNA damage (Lu et
al., 2008). We generated a cohort of TgT121;p21−/−;p53+/− mice, then used p53
immunostaining to evaluate p53 status in their tumors (Fig. 4 E–H). Among the tumors
examined (n=17) 76% were Type I tumors, 18% were Type II tumors, and a single mouse
developed both tumor types (Fig. 3 C). Since the Type I tumor frequency is significantly
higher than we observed in TgT121;Bax−/−;p53+/− mice (82% vs. 20%, p<0.05), we
conclude that selection against p53 remains high despite the absence of p21 function. These
results are consistent with a model where a p53-dependent function, which is not mediated
by p21, is actively selected against during brain carcinoma progression. Furthermore,
because p21 deficiency also causes hydrocephaly to a similar extent as Bax deficiency in
TgT121 and TgT121;p53+/− mice (data not shown), it also helps to rule out the possibility that
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hydrocephaly directly affects the selective pressure against p53 during CPE tumor
progression.
Given the importance of Bax in p53-dependent apoptosis in CPE, and our observation that
Bax deficiency reduced the selective pressure against p53 during CPE tumor progression, we
reasoned that the Bax gene itself might also be subject to selective pressure. Among human
cancers, reduced Bax expression is associated with poor clinical outcome in ovarian cancer
(Tai et al., 1998), metastatic breast adenocarcinoma (Krajewski et al., 1995), and squamous
cell carcinoma (Xie et al., 1999). Bax frameshift mutations have also been observed in
colorectal cancers (Rampino et al., 1997). We tested this hypothesis using in situ
hybridization to determine Bax gene status in TgT121;Bax+/− tumors (n=8). No tumors
showed loss of Bax expression (Fig. 5). Negative control Bax sense probes did not show
signal above background (data not shown). Although this assay cannot rule out Bax loss of
function caused by frameshift or missense mutation, we suspect Bax is not subject to high
selective pressure in this tumor setting. This result is perhaps not surprising, since Bax
mediates only 50% of p53-dependent apoptosis in our brain tumor model, and losing
additional pleiotropic p53 effects would confer greater advantage to tumors than Bax loss
alone.
Discussion
The p53 tumor suppressor plays important role in cell cycle control, apoptosis, senescence,
DNA repair, genomic stability maintenance, and regulation of angiogenesis. Together, these
diverse functions contribute to p53's tumor suppressive activity. Until recently, little was
known about which p53 function is essential for tumor suppression in vivo, and therefore
actively selected against during tumor progression. During lymphomagenesis apoptosis
appears to be the primary p53 function selected against (Schmitt et al., 2002), since selective
pressure for p53 loss was alleviated by reduced apoptosis levels (Eischen et al., 2001).
Because the roles of p53 effectors are likely cell-and condition-specific, it is unclear whether
apoptosis is also the essential target for selection during carcinoma progression.
To address this issue, we used the well-characterized brain carcinoma model in which CPE
tumors are induced by expression of a T antigen mutant, T121, transgene in choroid plexus
epithelial cells (Symonds et al., 1994). An advantage of the TgT121 model is the immense
selective pressure against p53 activity during CPE tumor progression. The frequencies of
p53 inactivation during TgT121 or TgT121;p53+/− tumor progression were 38% and 100%
respectively (Lu et al., 2001). To test the contribution of p53-dependent apoptosis to brain
carcinoma suppression, we reduced p53-dependent apoptosis by inactivating a single
downstream apoptotic gene, Bax. The absence of Bax activity (TgT121;Bax−/−) completely
suppressed the inactivation of p53, compared to the one-third of tumors derived from
TgT121;Bax+/+ mice that showed p53 inactivation. These results are consistent with our
hypothesis that the reduced level of Bax-mediated apoptosis alleviates the selective pressure
against p53.
A potential confounding factor in our experiments was the shortened lifespan of
TgT121;Bax−/− mice compared to TgT121;Bax+/+ mice (9 weeks vs. 32 weeks) that likely
results from the combination of rapid tumor progression and high incidence of severe
hydrocephaly. A shorter time frame might be insufficient to lose both p53 alleles required to
reveal the Type I phenotype. To avoid this potential problem, we analyzed tumor
progression in mice harboring a single p53 null allele (TgT121;Bax+/−;p53+/− and
TgT121;Bax−/−; p53+/− mice), since TgT121;p53+/− mice develop Type I tumors (p53
inactive) with much shorter latency than TgT121;p53+/+ mice. Even in the sensitized
background of p53 heterozygosity, the absence of Bax activity significantly reduced
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selective pressure against p53. To further exclude the possibility that severe hydrocephaly
directly affected selective pressure against p53, we also analyzed TgT121;p21−/−; p53+/−
mice, which have survival times similar to TgT121;Bax−/−;p53+/− mice, and also develop
severe hydrocephaly. The selective pressure against p53, evidenced by the high incidence of
Type I tumors, was not diminished by the p21 null background. We conclude a shorter
lifespan associated with hydrocephaly does not preclude the Type I tumor phenotype.
Instead, Bax-mediated apoptosis rather than p21 function, is the target of selective pressure
in tumors derived from brain epithelial cells.
Our studies also revealed notable distinctions between the brain carcinoma and B-cell
lymphoma models. In the lymphoma model, Bcl-2 over-expressing tumors advance to a
phenotype that is morphologically indistinguishable from p53-deficient tumors, indicating
that apoptosis alone is sufficient for tumor progression (Schmitt et al., 2002), even though
others have shown non-apoptotic p53 functions also contribute to lymphoma tumor
suppression (Liu et al., 2004; Ludwig et al., 1996; Post et al., 2009; Rowan et al., 1996). In
contrast, in the brain carcinoma model, p53 status corresponds to distinctive tumor biology
and behavior. Tumors that completely lose p53 activity (Type I) show tumor phenotypes
associated with more aggressive and malignant tumors; whereas, tumors that maintain p53
activity (Type II), despite the absence Bax activity, show a comparatively less aggressive
phenotype (Table 1). Therefore, p53-dependent pathways other than Bax-mediated apoptosis
determine the advancement to malignancy unlike the lymphoma model. Other studies from
our lab also point to the importance of losing p53 functions other than apoptosis during
tumor progression. We have also characterized tumors derived from TgT121 mice harboring
p21 and/or gadd45 null alleles. Only p53 inactivation, but not loss of Bax, p21, gadd45 (or
p21 and gadd45 combined), leads to aggressive brain carcinoma (Type I tumors). p53 also
appears to play a significant role in angiogenesis inhibition among CPE carcinomas, which
we are currently characterizing (Yin et al. unpublished results). Taken together, these
observations support our interpretation that the selective pressure for p53 inactivation is due
primarily to its role in apoptosis, while inactivating other p53-mediated functions
contributes to further tumor progression.
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Figure 1. Choroid plexus (CP) tumor progression in TgT121 mice with and without Bax gene
deficiency
Two types of CP tumors develop in TgT121 mice. Type I tumors are homogeneous tumors
with larger overall tumor volume, greater cell density, with abundant blood vessels and peri-
vascular CP cell polarity (A, C). Type II tumors show dysplastic cell morphology with
pleomorphic nuclei, and lower nuclear:cytoplasmic ratio. Type II tumors also have relatively
smaller overall volume, lower cell density, an little angiogenesis (B,D). TgT121;Bax−/− mice
develop Type II tumors (E) show and hydrocephaly (F). Images in panels C and D were
captured at higher magnification.
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Figure 2. p53 status correlates with tumor histology
We used p21 RNA in situ hybridization to determine p53 status in Type I tumors (A,B,E and
F) and Type II tumors (C, D, G and H) derived from TgT121 mice with different Bax
genotypes: Bax+/+ (A–D), Bax+/− (E), and Bax−/− (H). p21 RNA in situ hybridization was
performed on tumor sections (n=8 Type I and n=8 Type II tumors) using an antisense p21
riboprobe and viewed by dark-field microscopy (B,D,F and H). Adjacent sections were
stained with H & E and viewed by bright-field microscopy to show the location and
morphology of the CP (A,C,E and G). No p21 expression is detected in Type I tumors (B
and F), indicating p53 activity is lost in these tumors. In contrast, all Type II tumors
maintain p21 expression, indicating p53 is still functional. All pictures are equal
magnification (bar=200 µm).
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Figure 3. Bax deficiency decreases the frequency of p53 inactivation, associated with Type I
tumor histology
(A) Bax deficiency reduces the frequency of Type I tumors. Some of the Type I and Type II
tumors were analyzed by p21 RNA in situ hybridization to confirm p53 status as shown in
Figure 2. (B) Surivival curves of mice with different genotypes as analyzed in (A). (C) Bax
deficiency decreases selective pressure for p53 inactivation in TgT121 tumors that harbor a
single p53 allele. The vast majority of tumors derived from Bax null mice are Type II tumors
(p53 active), indicating p53 loss is greatly decreased. In contrast, p21 nullizygous mice,
which show a similar lifespan and incidence of hydrocephaly as Bax nullizygous mice, still
retain high p53 inactivation rates, indicating the effect is Bax-specific. Some of the tumors
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were analyzed by p21 RNA in situ hybridization as shown in Figure 4. (D) Survival curves
of mice with different genotypes analyzed in (C). (Fisher’s exact test was used to compare
tumor type distribution differences between different groups, ** indicates P<005).
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Figure 4. p53 status corresponds to tumor histology
Type I (A,B and E,F) and Type II (C,D and G,H) tumors are derived from TgT121;p53+/−
mice. H&E staining (A, C, E, G) were used to show the tumor morphology. p21 RNA in situ
hybridization (B, D) and immunohistochemistry (F, H) were used to examine p53’s
functional status.. In mice that harbor Bax mutant alleles p21 RNA in situ hybridization
reveals p53 function is lost in the Type I tumors (B), but not in the Type II tumors (D).
Representative examples of Type I (n=8) and Type II (n=8) are shown. Among p21
nullizygous mice (F,H), immunostaining also shows tumor histology corresponds to p53
status (n=5 for each tumor type). Consistent with our previous results, all Type I but none of
the Type II tumors show loss of p53 activity.. Panel A, B, E, F, G, and H are of lower
magnification as indicated by the black bar in H. Panel C and D are of higher magnification
as indicated by white bars.
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Figure 5. Loss of Bax expression is not detected in TgT121,Bax+/− terminal tumors
Given the importance of apoptosis, we reasoned there may also be selective pressure against
a single active Bax allele. We analyzed Bax status in terminal stage TgT12;Bax+/− tumors
(n=8) by RNA in situ hybridization using a Bax riboprobe. Panel C is representative of these
results. Compared to Bax wild type (A) or nullizygous (B) controls, we see no evidence for
loss of Bax transcripts in TgT121;Bax+/− tumors.
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Figure 6. Two different tumor progression scenarios
(A) Among Type I tumors, the entirety of p53 functions are ablated by the spontaneous loss
of p53, yielding aggressive, advanced tumors. When we reduce Bax activity (B), we
decrease the selective pressure for p53 loss. Thus, Type II tumors maintain the pleiotropic
functions of p53, and develop tumors with distinct biology.
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Table 1
Distinguishing features of Type I and Type II Choroid Plexus brain carcinomas.
Type I Type II
Gross Morphology Greater tumor volume High cell density
Homogeneous Cells Perivascular polarity
Smaller tumor volume Low cell density Dysplastic Cells
No perivascular polarity
Tumor Blood Vessels Abundant vessels Fewer blood vessels
p53 status Inactive Active
Mol Cancer Res. Author manuscript; available in PMC 2012 April 1.
